Key Highlights

  • Polar Capital Global Healthcare Trust (LSE:PCGH) closed at 458p on 3 November 2026, up around 1% on the day and close to its 52-week high of 460p.
  • The trust sold 100,000 shares from treasury at 457p on 3 November, a sign that Demand for its shares is strong enough to issue stock at or above NAV.
  • The shares have risen around 30% over the past year, up from a 52-week low of 320p.
  • Total Assets were around £463 million at 30 September 2026, the end of its financial year.
  • The trust has outperformed its MSCI ACWI Healthcare benchmark over several periods and has traded close to NAV, at times on a small premium.

Why Polar Capital Global Healthcare Trust (LSE:PCGH) Is in Focus Today

Polar Capital Global Healthcare Trust (LSE:PCGH) is in focus on 3 November 2026 after its shares closed at 458p, up around 1%, and the trust announced the sale of 100,000 ordinary shares from treasury at 457p each. Reissuing shares from treasury is only possible when a trust trades at or above its net asset value, which is unusual for Investment trusts in recent years, when many have suffered from wide discounts.

The FTSE 250 trust has become a talking point among investors looking for exposure to the global healthcare sector, which has rebounded after a difficult period of pressure from drug pricing, tariffs and regulatory concerns. With the shares close to their 52-week high, investors are discussing whether healthcare is set for a sustained recovery as an out-of-favour sector with improving sentiment.

A Strong Year for the Trust

The shares have climbed around 30% over the past year, from a 52-week low of 320p in July 2025 to a high of 460p in early July 2026. Recent trading has kept the stock in a range of roughly 420p to 460p, with the latest move pushing it back towards the top of that range.

Polar Capital Global Healthcare Trust (LSE:PCGH) has delivered relative outperformance against its benchmark, the MSCI ACWI Healthcare index in sterling, over several periods. Analysts have noted that the trust's performance has been achieved despite headwinds, including policy concerns in the US healthcare market. Some relative performance was lost by not holding certain large pharmaceutical stocks that performed strongly, such as Johnson & Johnson and Merck & Co.

Premium, Tender and Shareholder-Friendly Reforms

In recent years, the trust introduced shareholder-friendly reforms, including a tender offer that received tenders for around 27 million shares. These changes have been well received and helped narrow the discount. More recently, the trust has traded close to NAV and at times on a small premium, such as a 1.2% premium in July 2026.

The trust now holds around 16.1 million shares in treasury, giving it the flexibility to reissue shares when demand exceeds supply. Total voting rights stand at around 108 million shares. Selling shares from treasury at a premium is accretive to NAV per share for existing shareholders.

Investment Approach

The trust is managed by Polar Capital, with lead managers James Douglas and Gareth Powell. It invests in a global portfolio of healthcare companies, including pharmaceuticals, biotechnology, medical technology, healthcare services and life sciences tools. The managers have maintained an overweight position in biotechnology, citing positive views on innovation in the sector, while expressing caution about slowing topline growth, a lack of new product cycles and valuations in parts of the market.

The trust is focused primarily on capital growth, paying a small semi-annual dividend. Its most recent interim Dividend of 1.2p per share was paid on 28 August 2026. The ongoing charge is around 0.92%, with gross gearing of around 8%.

The Healthcare Sector Backdrop

Healthcare stocks have faced a challenging few years, with concerns over US drug pricing reforms, tariffs, Medicare negotiations and regulatory uncertainty weighing on valuations. However, sentiment has improved during 2026 as many of these risks have become clearer and attention has returned to innovation, including obesity treatments, oncology and gene therapies. Healthcare's defensive qualities have also attracted investors seeking Diversification away from technology-heavy markets.

Key Risks

Risks include US policy changes affecting drug pricing and healthcare spending, clinical trial failures, regulatory decisions, currency movements between the US dollar and sterling, and the potential for the trust to move back to a discount if sentiment towards healthcare weakens. The use of gearing amplifies both gains and losses.

What Investors Are Watching Next

The trust's financial year ended on 30 September 2026, and investors will look forward to the annual results, expected in early 2027, which will reveal full-year NAV performance against the benchmark. Daily NAV publications, further treasury share sales, sector developments in US healthcare policy and progress in biotechnology innovation will all be closely watched. Whether the trust can sustain a premium to NAV will be an important indicator of investor demand.